arly graft occlusion after cerebral revascularization occurs in approximately 5%-10% of cases despite advancements in surgical technique and pharmacological treatments. 41, 42, 53 Although rare, graft vasospasm remains a formidable and potentially lethal complication that affects multiple surgical specialties, 28 including plastic and reconstructive surgery, cardiac surgery, and neurosurgery. Patency and spasm rates vary by graft type, with arterial grafts currently preferred for revascularization procedures over venous grafts due to their lower risk of developing intimal hyperplasia and atherosclerosis, and greater long-term patency rates.
arly graft occlusion after cerebral revascularization occurs in approximately 5%-10% of cases despite advancements in surgical technique and pharmacological treatments. 41, 42, 53 Although rare, graft vasospasm remains a formidable and potentially lethal complication that affects multiple surgical specialties, 28 including plastic and reconstructive surgery, cardiac surgery, and neurosurgery. Patency and spasm rates vary by graft type, with arterial grafts currently preferred for revascularization procedures over venous grafts due to their lower risk of developing intimal hyperplasia and atherosclerosis, and greater long-term patency rates. 11 Nevertheless, long-term failure of arterial grafts still occurs in 2%-18% of cases, and arterial conduits have a significantly greater risk of vasospasm. Whether from occlusions or flow-limiting vasospasm, perfusion deficits in downstream territories from graft compromise can have devastating clinical consequences. 17, 25, 38 Despite extensive study to date, the exact cause of graft vasospasm remains unclear, and there is no single effective spasmolytic agent for preventing graft vasospasm. 27, 55 While complex pharmacological antispastic protocols have been proposed in coronary bypass grafting (often involving systemic vasodilators), their use in cerebrovascular bypass is generally limited by the need to maintain cerebral perfusion in these patients. 31 Botulinum toxin (BTX) is a potent neurotoxin widely used for the treatment of a variety of spastic and hyperactive autonomic conditions. 12, 33 The potent spasmolytic properties of BTX have sparked interest in its possible application for the prevention of graft spasm. In this review, we examine the current state of knowledge regarding BTX as it relates to graft vasospasm prevention, with a focus on revascularization conduit anatomy, physiology, and vasomotor mechanistic pathways.
Background Graft Vasospasm and Current Treatment Options
Multiple factors affect vessel wall contractility and must be considered during graft selection and evaluation/ optimization of potential spasmolytic agents. In addition to physical and chemical stimuli, vessel contractility is determined by anatomical features such as wall structure and the density and composition of receptors ( Fig. 1) , both of which can be affected by patient age and comorbidities such as atherosclerosis, hypertension, and diabetes. 25, 28, 30, 35, 58 Although it is known that dynamic changes in blood vessel diameter are mediated by vascular smoothmuscle cells (VSMCs) and vessel elasticity is determined by the amount of elastic laminae in the vessel wall, 24, 25 less is known about vasomotor receptor composition, which is only described in select arteries and may vary within different segments of the same artery. 24, 25, 29, 55 Despite their higher contractility, the common utilization of limb arteries in cerebrovascular bypass due to their ease of access and harvest makes the development of effective antispastic treatments critical. 24, 52 The extensive research on coronary artery bypass graft spasm possesses mixed relevance for cerebral revascularization. 24, 27, 29, 55 Given the multifaceted nature of vasospasm, variability of revascularization conduits, and pharmacological agents each targeting different pathways, a common conclusion of this work has been that there is no single ideal spasmolytic agent. Hence, complex spasmolytic protocols with combinations of different vasodilators applied pre-, intra-, and postoperatively, including both systemic and topical applications, have been developed. Besides emphasizing the importance of atraumatic graft harvest, these protocols typically contain papaverine or calcium channel antagonists (e.g., verapamil or nicardipine) and a nitrate (e.g., nitroglycerin). 24, 27 The utility of these protocols, which emphasize systemic vasodilator therapy, is limited in cerebrovascular bypass patients given the need for blood pressure/cerebral perfusion maintenance in the postoperative period. 31, 60 Additionally, the effects of intraoperative preventive and postoperative salvage vasodilators such as verapamil or papaverine are typically short-lived, and may require repeat interventions with increasing complication risks. 7, 19, 37 Addressing these limitations, the ideal therapeutic agent would be safe, longlasting, and quickly and easily applied intraoperatively for spasm prevention rather than treatment.
BTX-A as a Spasmolytic Agent: Classic Concepts
BTXs are potent biological toxins produced by anaerobic, gram-positive spore-forming bacteria from the Clostridium genus. There are 7 well-known, serotypically different BTXs (A-G) produced by 6 distinct groups
FIG. 1. Factors involved in vasoreactivity.
Vasoreactivity is determined not only by external/systemic factors (presence of physical stimuli and vasoactive substances), but also by intrinsic anatomical and physiological contractile properties of blood vessels as dictated by the density and composition of receptors and vessel wall structure.
of clostridia. 56 The primary BTX mechanism of action is cholinergic neuromuscular transmission blockade through inhibition of the release of acetylcholine from nerve terminals. 33, 51, 56 Specifically, BTX binds to a polysialoganglioside receptor on the presynaptic membrane and enters the nerve terminal via receptor-mediated endocytosis. The light chain of the BTX is a metalloproteinase that then cleaves one or more proteins from the soluble N-methylmaleimide sensitive factor attachment protein receptor complex that mediates synaptic vesicle exocytosis. BTX-B, -D, -F, and -G cleave vesicle-associated membrane protein, while BTX-A and -E cleave synaptosomal-associated protein-25 (SNAP-25), and BTX-C cleaves SNAP-25 and syntaxin. 33, 56 Although this BTXmediated cholinergic neural transmission blockade is irreversible, the duration of BTX paralytic activity varies significantly depending on toxin type, dose, species, and type of cholinergic nerve terminals targeted (autonomic or skeletal muscle). 51 BTX-A, one of the most commonly used subtypes, induces skeletal muscle paralysis that can be detected 2-3 days after injection and typically reaches its maximum at 1-2 weeks. This effect is gradually lost over time as nerve terminals are remodeled, with complete restoration of neural transmission to baseline levels in 3-4 months. 51 Currently, BTX is FDA approved for a very limited number of spastic conditions, with the majority of the more than 50 reported therapeutic applications being unlabeled, including hemifacial spasm, hyperhidrosis, headache, urinary incontinence, and Raynaud's phenomenon.
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BTX-A Utility in Vasospasm Prevention: Relevant Animal Studies
To date, BTX use has been reported in 6 animal studies evaluating its effects on microvascular anastomosis patency, vessel diameter, and response to vasospastic challenge on in situ blood vessels or grafts (Table 1) . 5, 14, 18, 34, 45, 48 In these studies, rat (n = 5/6) and rabbit (n = 1/6) models were used to evaluate various BTX types (n = 3 BTX-A, n = 2 BTX-B, and n = 1 BTX-C), doses (1-1500 IU), application methods (injection, direct application to the vessels in situ or in a tissue bath), and target vessels (femoral, aortic, and posterior auricular) with variable follow-up (30 minutes to 28 days). BTX efficacy was reported in all of these studies, demonstrating its utility for vasospasm prevention. 14, 18, 34, 48 Specifically, BTX improved microvascular anastomosis patency rates 18, 48 and counteracted vasospastic challenges from phenylephrine, 14, 34 potassium chloride (KCl), 45 norepinephrine (NE), 45 and cold, 14, 18, 34 with these effects detectable as early as 30 minutes 45 after treatment. The spasmolytic potential of BTX in these studies was shown to be dependent on both dose and application time. 5, 45 Multiple reports on the effects of BTX in animal models of free and pedicled cutaneous, myocutaneous, and muscular flaps also support a potentially multifaceted mechanism of action. We identified 15 animal studies to date (Table 2) where the effects of BTX-A (n = 14) and BTX-B (n = 1) on flap viability, vasodilation, blood flow, angiogenesis, and inflammation were evaluated. 1,6-8, 10, 22, 32, 36, 39, 40, 49, 50, 54, 57,62 In these studies, a rat model was most commonly used (n = 14/15) and there was significant variability in BTX dose (0.1-20 IU), application method (subdermal, intradermal, subcutaneous, intramuscular or perivascular injection, direct application to the vessels, or tissue bath), treated flaps (random cutaneous, abdominal or dorsal cutaneous, transverse rectus abdominis myocutaneous, cremaster, spinotrapezius, or gastrocnemius muscular), and evaluation time points (5 minutes to 21 days). Better flap survival rates, 10, 22, 32, 36, 39, 50, 54, 57 increased angiogenesis and angiogenic marker expression, 36, 39, 40, 49, 50, 54 improved blood flow, 54, 57 vasodilation, 8, 39, 50, 62 and reduced inflammation and inflammatory marker expression 1, 6 were observed in the BTX treatment groups as compared to controls. Interestingly, BTX-A also improved random cutaneous flap survival in rats after short-and long-term tobacco exposure, demonstrating its potential efficacy for the prevention of reconstructive and revascularization surgery complications in smokers. 10, 36 Although these animal studies provide valuable insights into the potential benefit of BTX in revascularization surgery, marked differences in innervation and response to spasmogens have been demonstrated between human and animal blood vessels. 26, 28, 29 The first translational application of BTX-A for cerebrovascular bypass graft spasm prevention in humans was only recently published. 63 
Potential Mechanisms of BTX A-Mediated Vasospasm Prevention BTX and Adrenergic Vascular Innervation
Understanding the spasmolytic effects of BTX requires a mechanistic understanding of vasoconstriction. Postganglionic sympathetic axons form a plexus at the adventitia-media border in most arteries, arterioles, and veins across animal species, including humans. 68, 70 Norepinephrine (NE), produced in sympathetic nerves, is released from perivascular axon varicosities after sympathetic stimulation and binds to VSMC postsynaptic a and b adrenoreceptors. NE-induced VSMC contraction in most major arteries is thought to be primarily mediated by postsynaptic a 1 adrenoreceptor activation, with variable contribution from a 2 receptors (Fig. 2) , 23 although the relative contributions of a 1 and a 2 adrenoreceptors to vasoconstriction depends on the anatomical location and segment of the vessel. In fact, in limb arteries the a 2 adrenoreceptor role in vasoconstriction increases when moving proximal to distal, 23 a finding that, when combined with the predisposition of the distal end of grafts to vasospasm, suggests a potentially important role of a 2 receptors in this process. 55 The affinity of BTX for cholinergic transmission blockade has been found to be related to the abundance of highaffinity acceptor sites on cholinergic neurons. 9 Although noncholinergic nerve terminals have a relatively low number of these acceptor sites, BTX can still be taken up via low-affinity sites if its concentration is high enough.
9,44
Moreover, while BTX-A cleavable SNAP-25 has been found in sympathetic axons innervating guinea pig blood vessels, NE-mediated vascular constriction was shown to be reduced after BTX-A administration with only partial cleavage of SNAP-25. 43, 44 In light of these findings, it was hypothesized that BTX-A might also be inhibiting adrenergic neurotransmission via a mechanism distinct from SNAP-25 cleavage. 44 A recent study utilized a 1 and a 2 receptor blockers to indirectly examine the mechanism of BTX A-mediated vasodilation in rat cremaster muscle microvasculature. 62 Sympathetic blockade seemed to be the likely mechanism, as BTX-A and adrenergic antagonist administration caused similar levels of vasodilation when applied separately, while BTX application after adrenergic antagonist administration caused no additional vasodilation. Another, more recent study evaluated the effects of BTX-A injection on the survival of random dorsal cutaneous flaps in a rat model, 54 and reported significantly improved flap survival, increased blood flow, and elevated expression of angiogenesis markers and endothelial nitric oxide synthase (eNOS) in the BTX A-treated as compared to the control group. Interestingly, flap tissue NE levels, as measured by highperformance liquid chromatography assay, were found to be significantly reduced immediately and 3 days after flap elevation in the BTX group (3 and 6 days after BTX-A treatment, respectively), suggesting that BTX A-mediated blockade of NE release might be contributing to its vasodilatory effects (Fig. 2) . Although the reduction of NE found 3 days after BTX-A treatment in this work is likely mediated in part via SNAP-25 cleavage, earlier time points after BTX-A treatment were not investigated, leaving open questions regarding the mechanisms of early BTX-A effects seen when applied to cerebral revascularization and Raynaud's phenomenon (discussed below). Although these studies provide valuable insights into the possible mechanisms of BTX-A vascular spasmolytic activity, they may not be directly translatable to humans given the arterial graft variability and differences in small animal versus human vascular innervation.
Insights From BTX-A Utility in the Treatment of Raynaud's Phenomenon
Raynaud's phenomenon is characterized by an exaggerated vasospastic response to cold or emotional stress stimuli in cutaneous arterioles. 20, 46, 71 The first report of BTX-A in patients with Raynaud's phenomenon was published in 2004. 64 Since then, multiple case series have demonstrated that direct perivascular BTX-A injections can provide rapid and long-lasting digit vasospasm relief. 46, 47, 69 Immediate pain relief was reported in more than 80% of patients, while improved digit perfusion (as evaluated by laser Doppler scans) was achieved within 30 minutes of injection in about 70% of patients, with a striking 300% flow improvement as early as 15 minutes after injection. 47 Notably, the effect of BTX-A in this setting appears to be prolonged, ranging from 13 to 59 months after a single injection. 47 Direct vasodilatory effects of BTX have also been reported in a rat model as early as 5 minutes after treatment, with a maximum effect seen at 15 minutes. 62 This differs from classic BTX-A characteristic effects, which have a known delay of several days and a duration of approximately 3-4 months. 46, 47, 51 Insights from the current literature on BTX-A indicate that the mechanism of vasospasm prevention is likely different from the classic paradigm. 
BTX-A and RhoA/ROCK Pathway
Growing evidence also demonstrates ras homolog gene family member A (RhoA)/rho-associated protein kinase (ROCK) pathway involvement in not only hypertension pathogenesis via increased inflammation, VSMC contractility, and endothelial dysfunction from negative regulation of the nitric oxide (NO) pathway, 16, 59, 61, 72 but also in graft vasospasm via similar mechanisms. 28 Takagi et al. investigated the effects of the ROCK inhibitor fasudil on radial artery graft vasospasm prevention. 65 Their findings showed an increase of in situ free blood flow with a corresponding decrease of myosin phosphatase targeting subunit 1 (MYPT1) and myosin light chain (MLC) phosphorylation that strongly counteracted the effects of major vasoconstrictors (NE and 5-hydroxytryptamine). Enhanced ROCK activity was also identified in skeletonized, spastic radial arteries as compared to nonmanipulated, nonspastic arteries, indicating that mechanical stimulation-induced vasospasm is likely mediated via the ROCK pathway as well. Moreover, ROCK pathway inhibition via abolished MYPT1 and MLC phosphorylation yielded a greater increase of in situ free blood flow as compared to that produced by the widely used antispastic agent verapamil, which showed no effect on ROCK. 65 Currently, however, the clinical use of fasudil is approved only in Japan and China.
The two main mechanisms of ROCK-mediated upregulation of VSMC contractility are calcium-dependent translocation of a 2c adrenoreceptors from the Golgi apparatus to the plasma membrane, and inhibition of myosin light chain phosphatase (MLCP; Fig. 2) . 61 Findings from Smith et al. 61 also demonstrate that ROCK activity (specifically, phosphorylation of MYPT1) and ROCK expression itself can change independently, as MYPT1 phosphorylation activity can increase while ROCK expression remains unchanged in hypertensive as compared to normotensive subjects. This underlines the distinction between ROCK expression and the functionality of its downstream effec-
FIG. 2.
RhoA/ROCK and adrenergic pathways mediating VSMC contraction. The ROCK pathway is primarily activated by vasoconstrictive substance binding to a G protein-coupled receptor and activating guanine nucleotide exchange factor (GEF). It can also be activated by reactive oxygen species (ROS) produced by the VSMC mitochondria upon cold exposure or via mechanical stimulus. In the case of cold exposure, activated ROCK promotes a 2c receptor recruitment from the endoplasmic reticulum to the cell membrane. Phosphorylation of the MLC by MLC kinase (MLCK) activated by Ca 2+ -calmodulin is the main molecular event mediating VSMC contraction. VSMC contraction can also be promoted by MLCP (which mediates MLC dephosphorylation and subsequent inhibition) inactivation by the ROCK downstream effector MYPT1. Adrenergic VSMC contraction occurs via two pathways depending on which receptor is activated. NE binding to the a 1 receptor activates phospholipase C b (PLCb), which increases intracellular Ca 2+ levels mediating MLCK activation. NE binding to the a 2 receptor inhibits adenylyl cyclase (AC), subsequently preventing inactivation of MLCK. BTX A-mediated VSMC relaxation could be mediated via inhibition of the ROCK pathway (1-3), or by blocking release of NE from perivascular adrenergic nerves (4). 5-HT = 5-hydroxytryptamine; cAMP = cyclic adenosine monophosphate; GDP = guanosine diphosphate; GTP = guanosine triphosphate; IP 3 = inositol triphosphate.
tors, and provides a potential explanation for the recent controversial findings of BTX A-mediated Rho kinase upregulation in murine myocutaneous and skin flaps. 49, 57 In these and numerous other animal studies, improved flap survival, increased tissue perfusion, vasodilation, and angiogenesis after BTX-A pretreatment has been demonstrated. 6, 8, 39, 49, 57, 66 Hence, the reported upregulation of Rho kinase expression in response to BTX-A seems to be contradictory to its well-reported vasodilatory effects in animal models and Raynaud's phenomenon treatments in humans. 20, 46, 64 Accordingly, Schweizer et al. hypothesized that increased RhoA immunoexpression after BTX-A administration could result from a compensatory overexpression in response to functional inhibition, 57 however, no targeted investigations of BTX A-specific effects on RhoA downstream effectors in the ROCK pathway have been reported.
BTX-A and Other Vasoactive Substance Release
Evidence supporting other mechanistic pathways for BTX-mediated spasmolytic effects has also been reported. Calcitonin gene-related peptide (CGRP) is a known microvascular dilator found in sensory and motor nerve endings, 20, 67 and CGRP upregulation in rat cholinergic nerve terminals and neurons after BTX-mediated muscular paralysis has been found. 67 Substance P is a neuropeptide involved in neurogenic inflammation and endothelium-dependent NO-mediated vasodilation. 20 Although no significant CGRP and substance P overall immunoexpression differences in BTX A-treated muscular flaps as compared to controls has been demonstrated, prominent CGRP expression was specifically found in thick-walled vessels, while substance P expression was limited to the thin-walled vessels of BTX A-treated tissues.
1 Expression of vascular endothelial growth factor (VEGF), a factor in NO-mediated angiogenesis and vasodilation, has also been shown to be increased following BTX administration in multiple animal studies. 1, 39, 50 Although more detailed investigation is necessary, these findings indicate that the role of BTX in vasodilation is likely multifactorial.
BTX-A Clinical Use and Safety
BTX is currently FDA approved for therapeutic and cosmetic indications and has demonstrated an excellent safety profile in labeled as well as unlabeled applications. 3, 15 Serious adverse events such as death, generalized muscle weakness, dysphagia, respiratory insufficiency, and anaphylaxis after BTX injections have been rarely reported and are typically associated with excessively high toxin doses and serious predisposing comorbidities in affected patients. 15 Generalized side effects have been associated with retrograde axonal migration of BTX from the site of injection. [2] [3] [4] The proposed ex-vivo perivascular toxin application by soaking the graft in a reconstituted BTX-A solution intraoperatively during cerebral bypass does not involve injections. 63 Moreover, after approximately 30 minutes of soaking in BTX-A solution, the graft is thoroughly flushed and washed to remove any residual toxin, thus minimizing risks of local and systemic spread.
While more extensive studies determining optimal dosing and exposure times for BTX-A use are certainly necessary, the concentration of the toxin proposed in cerebral revascularization grafts is only 10 IU/ml. 63 As a comparison, recommended doses of BTX-A used in injection form for spastic disorders reaches up to 100 IU/ml, with total dosages of 360 IU per treatment session. 3 Similar to numerous currently practiced unlabeled BTX-A and other off-label medication uses, 12, 13 BTX-A use in graft vasospasm is unlabeled and will likely remain so given the costly and time-consuming nature of obtaining FDA approval for new indications of currently approved drugs. 21, 73 Unlabeled drug use, defined as prescribing currently available medications for an indication that does not have FDA approval (including unapproved patient populations, doses, or administration forms), 73 is nonetheless at the treating physician's discretion for indications that they believe are in the patient's best interests based on credible evidence.
21,73
Conclusions
Animal studies suggest that BTX effects on the vasculature likely reach beyond its classic cholinergic paradigm and involve multiple pathways. The optimal application conditions and therapeutic outcomes for BTX use in revascularization patients remain ill defined. Elucidating the role of BTX-A in graft spasm prevention will aid in determining whether and how the findings from animal studies are translated to clinical practice. This knowledge will aid in optimizing patients, conduit selection, and application conditions for BTX treatment. Based on experimental data and initial clinical reports of BTX-A for spasmolysis, the applications for BTX-A will likely extend to cardiac revascularization as well as reconstructive surgery.
